Wegovy for PCOS weight loss: what month 3 really looks like
Quick answer
The creator is in her third month of semaglutide (Wegovy) therapy for PCOS-related weight management and is self-administering subcutaneous injections to the abdomen, rotating between left and right sides weekly. Her described technique is broadly consistent with Novo Nordisk's approved labeling for injection site selection, though she omits guidance on periumbilical clearance and the long-term benefits of rotating between anatomical regions. Feeling a brief pinch sensation during injection is within normal parameters for the device.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @alexusdevon actually say?
She's starting her third month on Wegovy and addressing viewer feedback about injection sites. Her position: she prefers her stomach over her arms or thighs, but she does rotate locations within the abdomen, alternating sides each week. She also mentioned feeling the needle this time, describing it as "a little pinch" that doesn't hurt but is noticeable. That's the full scope of the injection-related claims here.
This is a practical, experience-based video, not a medical tutorial. She's sharing what works for her body and her comfort level, which is a reasonable thing to do. The question is whether what she's describing is actually safe and in line with clinical guidance, or whether her 216,000 viewers should be doing something different.
Does the science back this up?
Mostly, yes. Rotating injection sites within a single region like the abdomen is clinically acceptable, and semaglutide's prescribing information (Novo Nordisk, 2023) explicitly lists the abdomen as one of the approved injection sites alongside the thigh and upper arm. She's not wrong to use her stomach.
The rotation-within-a-region approach she describes, alternating left and right sides weekly, aligns with standard nursing guidance on subcutaneous injections. A 2014 review by Hirsch et al. in the journal Diabetes Technology and Therapeutics found that site rotation within a region reduces the risk of lipohypertrophy, a lump-forming condition caused by repeated trauma to the same tissue. Lipohypertrophy can impair drug absorption, so rotation isn't just comfort advice, it's pharmacokinetically relevant. She's doing the right thing here, even if she doesn't frame it in those terms.
What did they get wrong (or right)?
Honestly, she got the fundamentals right. Rotating within the abdomen is acceptable. Avoiding the exact same spot each week is good practice. The "little pinch" sensation she describes is normal and not a sign of improper technique.
One thing worth flagging: she doesn't mention the two-inch rule, meaning injections should be placed at least two inches from the navel to avoid less effective absorption in that area. Novo Nordisk's guidance and general subcutaneous injection protocols both specify this. It's a small but real gap in what she's sharing.
Also, sticking exclusively to the abdomen for the long term isn't ideal. Research on insulin injections, which use the same subcutaneous tissue as semaglutide, shows that using only one body region over months increases lipohypertrophy risk even with within-region rotation (Gentile et al., 2016, Journal of Diabetes Science and Technology). She says she may change in the future, which is the right instinct.
What should you actually know?
Subcutaneous injection technique matters more than most people think, and TikTok is not a reliable place to learn it. Here's what the clinical evidence actually supports:
- All three approved sites for semaglutide, abdomen, thigh, upper arm, are pharmacokinetically equivalent per Novo Nordisk's label. You can use your stomach, but you're not getting a special benefit from it over other sites.
- Rotate at least one inch from your previous injection within a region. Alternating sides of the abdomen weekly, as she does, is a reasonable way to do this.
- Stay at least two inches away from your navel. Periumbilical tissue has variable absorption characteristics.
- If you notice a firm lump, indentation, or thickened skin at an injection site, that's lipohypertrophy. Stop injecting into that spot and tell your prescriber.
- Feeling the needle is normal. Semaglutide auto-injectors use a small-gauge needle. A brief pinch sensation doesn't indicate a problem with technique.
If you're new to self-injection, your pharmacist or prescribing clinician should walk you through technique before you take injection tips from a social media video, including this one.
Bottom line: how worried should you be?
Not very, in this case. @alexusdevon isn't spreading dangerous misinformation. She's describing a reasonable, mostly correct approach to a real practical question about Wegovy use. The gaps in her guidance, no mention of the navel clearance rule, and the long-term case for rotating between body regions, are worth knowing. But this video isn't going to hurt anyone. It's a candid personal update, not a clinical protocol, and viewers should treat it accordingly.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Wegovy for PCOS weight loss: what month 3 really looks like, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
The creator is in her third month of semaglutide (Wegovy) therapy for PCOS-related weight management and is self-administering subcutaneous injections to the abdomen, rotating between left and right sides weekly.
FormBlends verdict
The creator is in her third month of semaglutide (Wegovy) therapy for PCOS-related weight management and is self-administering subcutaneous injections to the abdomen, rotating between left and right sides weekly. Her described technique is broadly consistent with Novo Nordisk's approved labeling for injection site selection, though she omits guidance on periumbilical clearance and the long-term benefits of rotating between anatomical regions. Feeling a brief pinch sensation during injection is within normal parameters for the device.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is in her third month of semaglutide (Wegovy) therapy for PCOS-related weight management and is self-administering subcutaneous injections to the abdomen, rotating between left and right sides weekly. Her described technique is broadly consistent with Novo Nordisk's approved labeling for injection site selection, though she omits guidance on periumbilical clearance and the long-term benefits of rotating between anatomical regions. Feeling a brief pinch sensation during injection is within normal parameters for the device.
- All three semaglutide injection sites (abdomen, thigh, upper arm) are pharmacokinetically equivalent per Novo Nordisk's 2023 prescribing information.
- Within-region rotation reduces lipohypertrophy risk. A 2014 Hirsch et al. review in Diabetes Technology and Therapeutics confirmed that repeated trauma to the same subcutaneous site impairs drug absorption over time.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- All three semaglutide injection sites (abdomen, thigh, upper arm) are pharmacokinetically equivalent per Novo Nordisk's 2023 prescribing information.
- Within-region rotation reduces lipohypertrophy risk. A 2014 Hirsch et al. review in Diabetes Technology and Therapeutics confirmed that repeated trauma to the same subcutaneous site impairs drug absorption over time.
- Injections should be placed at least two inches from the navel. This guideline, standard in subcutaneous injection protocols, was not mentioned in the video.
- Using only one body region for months raises lipohypertrophy risk even with within-region rotation, per Gentile et al. (2016) in the Journal of Diabetes Science and Technology.
- A brief pinch or needle sensation during semaglutide auto-injector use is normal and not a sign of incorrect technique.
- Lipohypertrophy (firm lumps or thickened skin at injection sites) is a real complication that can reduce how well the drug is absorbed. Any such changes should be reported to a prescriber.
- Social media injection technique videos, including this one, are not a substitute for in-person or pharmacist-led injection training when starting a new injectable medication.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Lex 🦋 · TikTok creator
216.3K views on this video
Starting my 3rd month so exicted! This month hopefully better results with staying on a diet + daily exercise! #glp1forweightloss #gp1journey #wegovyweightloss #wegovyupdate #wegovyjourney #pcosglp1 #pcosweightloss #pcos #weightloss #wegovy #gp1medication #weightlossupdate
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Lex 🦋, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.